Table 5 Literature data
From: Toxicity after radiochemotherapy for glioblastoma using temozolomide - a retrospective evaluation
Authors | Number of patients | Toxicity 3/4° leucocytes | Toxicity 3/4° thrombocytes | Remarks I | Remarks II |
|---|---|---|---|---|---|
Randomized trials | |||||
Athanassiou et al. 2005 [11] | 130 | 3.5% | 5.2% | 1 pat. died of sepsis | |
Stupp et al., 2005 [1] | 573 | 4% | 3% | Severe infections in 3% | |
Retrospective analyses | |||||
Armstrong 2008 [12] | 203 | Clinically significant lymphopenia in 45% of women and 6% of men | Abstract | ||
Combs et al. 2005 [26] | 53 | 2% | 0 | No severe late effects | temozolomide 50 mg/m2 |
Combs et al. 2008 [14] | 160 | Hematologic toxicity 5% (50 mg/m2) vs. 14% (75 mg/m2) | Premature discontinuation 6.5% vs. 14% | Comparison temozolomide 50 vs. 75 mg/m2 | |
Fiorica et al. 2010 [15] | 42 | 0 | 5% | ||
Gerber 2007 [16] | 52 | Neutro-penia In 18% | 15% | Mean duration 332 days [1-389 days] | 10% required platelet transfusions, 67% discontinued radiochemo-therapy |
Gerstein et al. 2009 [17] | 51 | Hematologic toxicity 14% | Premature discontinuation in 41% | ||
Jeon 2009 [27] | 79 | Hematologic toxicity 7.5% | 1 pat. with severe lung infection | ||
Kimple 2010 [19] | 32 | 3% | 0 | ||
Minniti et al. 2008 [20] | 32 | 3% | 3% | Pneumonia in 3% | |
Our data | 46 | 15% | 17% | 43% discontinued treatment | |